Yuka Yamamoto - Search Results

Year	Number of Results
2002	3
2003	9
2004	5
2005	6
2006	8
2007	9
2008	15
2009	11
2010	8
2011	15
2012	17
2013	15
2014	12
2015	10
2016	10
2017	13
2018	11
2019	16
2020	27
2021	29
2022	26
2023	16
2024	7

1

Texture Features of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer.

Norikane T, Ishimura M, Mitamura K, Yamamoto Y, Arai-Okuda H, Manabe Y, Murao M, Morita R, Obata T, Tanaka K, Murota M, Kanaji N, Nishiyama Y. Norikane T, et al. Among authors: yamamoto y. J Clin Med. 2024 Mar 12;13(6):1625. doi: 10.3390/jcm13061625. J Clin Med. 2024. PMID: 38541851 Free PMC article.

2

Polygenic effects on the risk of Alzheimer's disease in the Japanese population.

Kikuchi M, Miyashita A, Hara N, Kasuga K, Saito Y, Murayama S, Kakita A, Akatsu H, Ozaki K, Niida S, Kuwano R, Iwatsubo T, Nakaya A, Ikeuchi T; Alzheimer’s Disease Neuroimaging Initiative; Japanese Alzheimer’s Disease Neuroimaging Initiative. Kikuchi M, et al. Alzheimers Res Ther. 2024 Feb 27;16(1):45. doi: 10.1186/s13195-024-01414-x. Alzheimers Res Ther. 2024. PMID: 38414085 Free PMC article.

3

Predictive value of local control by 4'-[methyl-11C]-thiotymidine PET volume parameters in p16-negative oropharyngeal, hypopharyngeal, and supraglottic squamous cell carcinoma.

Ouchi Y, Kishino T, Miyashita T, Mori T, Mitamura K, Norikane T, Yamamoto Y, Hoshikawa H. Ouchi Y, et al. Among authors: yamamoto y. Nucl Med Commun. 2024 May 1;45(5):381-388. doi: 10.1097/MNM.0000000000001821. Epub 2024 Jan 22. Nucl Med Commun. 2024. PMID: 38247572

4

Feasibility of PiB positron emission tomography/computed tomography for treatment monitoring with Tafamidis in a patient with transthyretin cardiac amyloidosis.

Fujioka K, Norikane T, Takami Y, Yamamoto Y, Noma T, Nishiyama Y. Fujioka K, et al. Among authors: yamamoto y. J Nucl Cardiol. 2024 Mar;33:101816. doi: 10.1016/j.nuclcard.2024.101816. Epub 2024 Jan 20. J Nucl Cardiol. 2024. PMID: 38246259

5

Feasibility of ¹¹C-Pittsburgh compound B positron emission tomography/computed tomography for treatment monitoring with Tafamidis in a patient with transthyretin cardiac amyloidosis.

Fujioka K, Norikane T, Takami Y, Yamamoto Y, Noma T, Nishiyama Y. Fujioka K, et al. Among authors: yamamoto y. J Nucl Cardiol. 2024 Jan 5:101800. doi: 10.1016/j.nuclcard.2024.101800. Online ahead of print. J Nucl Cardiol. 2024. PMID: 38185410

6

Physiological myocardial ¹⁸F-FDG uptake pattern in oncologic PET/CT: comparison with findings in cardiac sarcoidosis.

Norikane T, Yamamoto Y, Takami Y, Mitamura K, Kobata T, Maeda Y, Noma T, Nishiyama Y. Norikane T, et al. Among authors: yamamoto y. Asia Ocean J Nucl Med Biol. 2024;12(1):1-10. doi: 10.22038/AOJNMB.2023.70254.1490. Asia Ocean J Nucl Med Biol. 2024. PMID: 38164236 Free PMC article.

7

Comparative evaluation of ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma.

Norikane T, Mitamura K, Yamamoto Y, Manabe Y, Murao M, Arai-Okuda H, Hatakeyama T, Miyake K, Nishiyama Y. Norikane T, et al. Among authors: yamamoto y. J Neurooncol. 2024 Jan;166(1):195-201. doi: 10.1007/s11060-023-04534-w. Epub 2023 Dec 31. J Neurooncol. 2024. PMID: 38160415

8

A Rare Epicardial Cytokeratin-Positive Interstitial Reticulum Cell Tumor.

Murao M, Norikane T, Yamamoto Y, Nishiyama Y. Murao M, et al. Among authors: yamamoto y. Korean Circ J. 2023 Dec;53(12):858-859. doi: 10.4070/kcj.2023.0240. Korean Circ J. 2023. PMID: 38111264 Free PMC article. No abstract available.

9

Stimulatory and inhibitory effect of antipsychotic agents including dopaminergic neuro-depressants on dopamine formation from p-tyramine mediated by cytochrome P450 2D6.

Niwa T, Yamamoto Y. Niwa T, et al. Among authors: yamamoto y. Drug Metab Bioanal Lett. 2023 Sep 14. doi: 10.2174/2949681016666230914115021. Online ahead of print. Drug Metab Bioanal Lett. 2023. PMID: 37711131

10

Higher longitudinal brain white matter atrophy rate in aquaporin-4 IgG-positive NMOSD compared with healthy controls.

Masuda H, Mori M, Hirano S, Uzawa A, Uchida T, Muto M, Ohtani R, Aoki R, Hirano Y; Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI); Kuwabara S. Masuda H, et al. Sci Rep. 2023 Aug 3;13(1):12631. doi: 10.1038/s41598-023-38893-1. Sci Rep. 2023. PMID: 37537208 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

247 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Results by year